CDK7-IN-18

• UNSPSC Description:

  CDK7-IN-18 is a potent inhibitor of CDK7. CDK7-IN-18 is a pyrimidinyl derivative compound. CDK7-IN-18 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 15)[1].

• Target Antigen:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk7-in-18.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1(CC[C@@H](CN1)NC2=NC=C(C(C3=CNC4=C(C=CC=C34)S(C)(=O)=NC#N)=N2)C(F)(F)F)C

• Molecular Weight:

  491.53

• References & Citations:

  [1]Guanpeng Qiu, et al. Pyrimidinyl derivatives, method for the production thereof and use thereof. Patent CN114249712A.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2765676-81-9